IN VITRO ANTIVIRAL SCREEN FOR HEPATITIS VIRUSES

“嗜肝DNA病毒体外抗病毒筛查”合同是一项 微生物学部肝炎项目的奋进 和传染病，NIAID，以方便调查人员在 他们对鉴定能够 改善/治疗R型肝炎慢性感染。 目标是 确定药物，以拯救超过3亿慢性携带者， 全世界的B型肝炎--仅美国就有100万-- 由病毒引起的进行性的、使人衰弱的疾病。 作为 DMID的临床前抗病毒药物开发的组成部分， 抗病毒筛选已经取得了很大的成功。 项目工作人员选择进入筛选过程的药物 评估它们抑制病毒的能力， 细胞，并为一些化合物的初步测定 组织培养模型中的作用机制。 如果合适， 推荐用于土拨鼠动物的进一步体内研究 由独立的NIAID合同资助的模式。 本合同为 用于筛选和选择由以下物质产生的化合物的载体： 大学的调查人员和小企业， 这样的内部能力和专业知识。

The "In Vitro Antiviral Screen for Hepadnaviruses" Contract is an endeavor by the Hepatitis Program of the Division of Microbiology and Infectious Diseases, NIAID, to facilitate investigators in their pursuit of identifying agents/compounds capable of ameliorating/curing hepatitis R chronic infection. The goal is to identify drugs to rescue the over 300 million chronic carriers of hepatitis B in the world--one million in the U.S. alone--from the progressive, debilitating illness caused by the virus. As an integral part of DMID's preclinical antiviral drug development, the antiviral screen has already met with a high degree of success. Drugs selected by Program staff for entry to the screening process are evaluated for their ability to inhibit the virus, toxicity to cells, and for some compounds preliminary determination of mechanism-of-action in a tissue culture model. If suitable they are recommended for further in vivo studies in the woodchuck animal model funded by separate NIAID contracts. This contract is a vehicle for screening and selection of compounds generated by university-based investigators and small businesses who do not have such in-house capabilities and expertise.